Periodic Reporting for period 1 - MMEM (Miniaturized Matrixed Enthalpy Metter - Portable, affordable, easy to operate, diagnostic device enabling a rapid & accurate diagnosis of a patient infected by antibiotic-resistant bacteria)
Reporting period: 2019-07-01 to 2020-06-30
GenoSmart's ultimate goal is to render the MMEM ready for market launch in Europe. This entails a number of technical and strategic objectives, including the completion of the product’s CPE detection capability, the clinical validation through a European clinical study, and exploitation of the results.
Being cost-effective, rapid, accurate and easier to use in on-site scenarios – one-by-one and all together – will lead to significant impact on the market and bring important benefit to humankind, starting in Europe and expanding world-wide. These parameters are critical factors in controlling the devastating effects of the antibiotic resistant bacteria pandemic, which may jeopardize treatment of patients’ who need procedures such as surgery, cancer treatment, child birth and more.
We plan to disseminate GenoSmart’s MMEM sample-to-result device in clinical laboratories, emergency rooms, doctor offices and other point-of-care locations. The most important parameters in the fight against rapidly spreading pandemics such as CPE, COVID-19 and others, are accurate, efficient, affordable, and timely diagnosis. The business potential stems from the urgent need for a prompt screening technology that would combine swiftness, accuracy, and a cost-effective detection method. GenoSmart’s solution will result in significant increase of diagnostic tests and will enable better management of the disease prevalence and spread in the population, in a cost-effective manner. The recent COVID-19 pandemic demonstrates the urgent need for GenoSmart’s rapid and affordable diagnostic solution, which can be readily adapted to any new and emerging pathological threat.